We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
-6.61%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$165M
AUM Growth
-$107K
Cap. Flow
+$56.4M
Cap. Flow %
34.21%
Top 10 Hldgs %
86.73%
Holding
18
New
3
Increased
9
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$18.4M
2
AXSM icon
Axsome Therapeutics
AXSM
+$15.4M
3
FOLD
Amicus Therapeutics
FOLD
+$12.7M
4
TRIL
Trillium Therapeutics Inc.
TRIL
+$6.87M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.61M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$4.13M
2
ACHN
Achillion Pharmaceuticals
ACHN
+$3.77M
3
XENT
Intersect ENT, Inc
XENT
+$2M
4
ARGX icon
argenx
ARGX
+$220K
5
TARA icon
Protara Therapeutics
TARA
+$140K

Sector Composition

Rank Sector Weight
1 Healthcare 95.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
1
Acadia Pharmaceuticals
ACAD
$4.38B
$25.5M 15.47%
603,517
+87,729
+17% +$3.61M
ZGNX
2
DELISTED
Zogenix, Inc.
ZGNX
$24M 14.58%
971,875
+505,000
+108% +$18.4M
INSM icon
3
Insmed
INSM
$23.5B
$16.4M 9.92%
1,020,797
+31,798
+3% +$754K
IOVA icon
4
Iovance Biotherapeutics
IOVA
$2.23B
$14.7M 8.92%
491,390
+37,500
+8% +$994K
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
$12.4M 7.51%
+1,340,395
New +$12.7M
AXSM icon
6
Axsome Therapeutics
AXSM
$11.8B
$11.2M 6.76%
+189,598
New +$15.4M
KPTI icon
7
Karyopharm Therapeutics
KPTI
$216M
$10.8M 6.55%
37,490
+10,716
+40% +$2.96M
ARGX icon
8
argenx
ARGX
$53.8B
$10.1M 6.12%
76,638
-1,500
-2% -$220K
NGNE icon
9
Neurogene
NGNE
$744M
$9.22M 5.59%
40,504
– –
ENTA icon
10
Enanta Pharmaceuticals
ENTA
$400M
$8.74M 5.3%
169,949
+8,000
+5% +$426K
ALLK
11
DELISTED
Allakos
ALLK
$7.95M 4.82%
178,662
+50,000
+39% +$3.42M
TRIL
12
DELISTED
Trillium Therapeutics Inc.
TRIL
$7.34M 4.45%
+1,818,181
New +$6.87M
AMRN
13
Amarin Corp
AMRN
$292M
$3.49M 2.11%
43,586
+1,500
+4% +$498K
KNSA icon
14
Kiniksa Pharmaceuticals
KNSA
$4.92B
$3.1M 1.88%
200,125
+34,807
+21% +$545K
ASND icon
15
Ascendis Pharma A/S
ASND
$17.1B
– –
-29,676
Closed -$4.13M
TARA icon
16
Protara Therapeutics
TARA
$230M
– –
-8,544
Closed -$140K
XENT
17
DELISTED
Intersect ENT, Inc
XENT
– –
-80,238
Closed -$2M
ACHN
18
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-624,956
Closed -$3.77M

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q1 2020 Portfolio in Review

As of Q1 2020, Fairmount Funds Management held 18 positions worth $165M, down 0.06% from $165M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Fairmount Funds Management deployed $56.4M of net new capital in Q1 2020, opening 3 new positions and adding to 9 existing holdings. Its largest new stake was Axsome Therapeutics: 189,598 shares worth $11.2M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was argenx, an estimated $220K trimmed.

  • Fairmount Funds Management's largest Q1 2020 buy was Axsome Therapeutics: 189,598 shares worth $11.2M.
  • Fairmount Funds Management added most to Zogenix, Inc. in Q1 2020, an estimated $18.4M increase.
  • Fairmount Funds Management's biggest Q1 2020 reduction was argenx, cutting an estimated $220K.
  • Fairmount Funds Management fully exited Ascendis Pharma A/S in Q1 2020, selling an estimated $4.13M.
  • Fairmount Funds Management's ten largest holdings make up 87% of its $165M portfolio in Q1 2020.
  • Fairmount Funds Management opened 3 new positions and closed 4 in Q1 2020.
  • Fairmount Funds Management's portfolio value fell 0.06% quarter-over-quarter to $165M.

Based on Fairmount Funds Management's 13F filing for Q1 2020, filed 8 May 2020.